May 2005
Volume 46, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2005
Inhibition of Experimental Angiogenesis of Cornea by Doxycycline
Author Affiliations & Notes
  • E. Aydin
    Ophthalmology, Tulane University Health Sciences Center, New Orleans, LA
    Ophthalmology, Gaziosmanpasa University, Tokat, Turkey
  • G.A. Peyman
    Ophthalmology, Tulane University Health Sciences Center, New Orleans, LA
  • M. Riazi Esfahani
    Ophthalmology, Tulane University Health Sciences Center, New Orleans, LA
    Ophthalmology, Tehran University Eye Research Center, Tehran, Iran (Islamic Republic of)
  • A.A. Kazi
    Ophthalmology, Tulane University Health Sciences Center, New Orleans, LA
    Ophthalmology, Isra University, Hyderabad, Pakistan
  • D.R. Sanders
    Ophthalmology, University of Chicago College of Medicine, Chicago, IL
  • Footnotes
    Commercial Relationships  E. Aydin, None; G.A. Peyman, None; M. Riazi Esfahani, None; A.A. Kazi, None; D.R. Sanders, Regenera Limited I, C.
  • Footnotes
    Support  Regenera Limited
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 4481. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      E. Aydin, G.A. Peyman, M. Riazi Esfahani, A.A. Kazi, D.R. Sanders; Inhibition of Experimental Angiogenesis of Cornea by Doxycycline . Invest. Ophthalmol. Vis. Sci. 2005;46(13):4481.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To evaluate the effect of topically administered doxycycline on experimental corneal neovascularization in rats. Methods: Chemical cauterization of cornea in 36 eyes of 36 Long Evans male rats was performed using silver nitrate/potassium nitrate sticks. The animals were anesthetized and treated in accordance with the ARVO statement on the use of animals in ophthalmic and visual research. Topical instillation of doxycycline at 0.05% (pH: 3.3), 0.1% (pH: 3.1), 1% (pH: 2.3), 2% (pH: 2.1), 2% (pH neutralized to 7.4), and normal saline continued for 7 days. The percentage area of the cornea covered by neovascularization and scar in each group was calculated separately using computer software on digital photographs. All corneas in the experimental and control groups were evaluated histopathologically. Results: The means of percent area of corneal neovascularization were determined in eyes given doxycycline: 0.05%, 69.8 ± 18.0%; 0.1%, 64.5 ± 14.0%; 1%, 56.4 ± 20.8%; 2%, 54.8 ± 6.0%; and 2% (pH neutralized), 36.2 ± 4.3%; this measurement in the control group was 69.4 ± 5.7%. The mean of percent area of neovascularization in the 2% doxycycline (pH neutralized) group was significantly less than the control group and the <1% doxycycline group concentrations (p < 0.05). The percent corneal neovascularization in the 2% (pH neutralized) doxycycline group was not significantly different than in the 1% and 2% doxycycline groups (p < 0.05). There was no significant difference in percent area of corneal scar between control and study groups (p > 0.05). Conclusions: Topically administered 2% (pH neutralized) doxycycline has antiangiogenic effects, which contributed to significant suppression on corneal neovascularization. This drug may be therapeutically beneficial in treatment of corneal neovascularization in clinical trials.

Keywords: neovascularization • drug toxicity/drug effects 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×